Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc_20100107

Arena Pharmaceuticals Inc patents


Recent patent applications related to Arena Pharmaceuticals Inc. Arena Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Arena Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Arena Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Arena Pharmaceuticals Inc-related inventors


Composition of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto

The present invention relates to certain compositions of a 5-ht2a serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. ... Arena Pharmaceuticals Inc

Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto

The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-n methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (compound i), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.. . ... Arena Pharmaceuticals Inc

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd).. ... Arena Pharmaceuticals Inc

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd).. ... Arena Pharmaceuticals Inc

Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia). ... Arena Pharmaceuticals Inc

Cannabinoid receptor modulators

Provided are certain methods useful in the treatment of cancer comprising administering a compound of formula ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor;. . ... Arena Pharmaceuticals Inc

Modified-release dosage forms of 5-ht2c agonists useful for weight management

The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.. ... Arena Pharmaceuticals Inc

Method of weight management

Provided are methods of determining if an individual is a responder to treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. ... Arena Pharmaceuticals Inc

Arena Pharmaceuticals, Inc.

. . ... Arena Pharmaceuticals Inc

Administration of an anti-obesity compound to individuals with renal impairment

The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.. ... Arena Pharmaceuticals Inc

Arena Pharmaceuticals, Inc.

. . ... Arena Pharmaceuticals Inc

Arena Pharmaceuticals, Inc.

. . ... Arena Pharmaceuticals Inc

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof

The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. . ... Arena Pharmaceuticals Inc

Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Imidazo[1,2-a]pyridine derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the 5-ht2a serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, gilles de ia tourette's syndrome, manic disorder, organic or nos psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, nos schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. ... Arena Pharmaceuticals Inc

05/18/17 / #the present invention relates to processes for preparing pyrazole derivatives of formula (i) and salts and pharmaceutical compositions of the salts thereof, useful as modulators of 5-ht2a serotonin receptor activity.

Arena Pharmaceuticals, Inc.

. . ... Arena Pharmaceuticals Inc

04/06/17 / #20170096398

Non-hygroscopic salts of 5-ht2c agonists

Salts of the 5-ht2c-receptor agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine, and dosage forms comprising them that are useful for, inter alia, weight management.. . ... Arena Pharmaceuticals Inc

03/02/17 / #20170057931

Substituted pyridazines as prostacyclin receptor modulators

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd).. ... Arena Pharmaceuticals Inc

03/02/17 / #20170057924

Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto

The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (compound i), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.. . ... Arena Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Arena Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Arena Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###